Download
1 / 4
40 likes | 52 Views
Continuous bioprocessing involves manufacturing biopharmaceuticals where continuous unit operations are physically connected with minimal hold volume. Some of the major factors driving the growth of this market include the growing demand for biopharmaceuticals, technological developments in continuous bioprocessing, product launches in the area of continuous bioprocessing, and global initiatives supporting the adoption of biopharmaceuticals.
E N D
??? ????????? ???????? ????????????? ?????????????" " - -????? ??? ??????????? ???????? ?? " "?????????? ?????????? ??????????? ??????
Continuous Bioprocessing Market –2021-2028 According to a new market research report “Continuous Bioprocessing Market By Product (Filtration, Chromatography, Centrifuges, Consumables), Application (Commercial {Vaccines, Monoclonal Antibodies}, R&D), End User (Pharmaceuticals, Biotechnology, CROs), and Geography –Global Forecast 2028”,published by Meticulous Research, the continuous bioprocessing market is expected to grow at a CAGR of 23% from 2021 to reach $429.12 million by 2028. Continuous manufacturing is a new trend in the manufacturing industry. From automobiles to paper, industries are adopting continuous manufacturing to improve efficiencies and increase profits. Due to the growing demand for innovative and complex therapies and competition, biopharmaceutical manufacturers are reconsidering manufacturing methods (shifting from batch to continuous manufacturing). Although batch manufacturing is the most preferred method, continuous manufacturing is increasingly accepted in the pharmaceutical industry. Download Free Sample Report Now @ https://www.meticulousresearch.com/download- sample-report/cp_id=5079 Over the years, many advances have been made in bioprocessing to cut costs, improve product yield, and streamline upstream and downstream processing integration. Advances in upstream processing have been focused on key areas like increasing volumetric productivity through process intensification, increasing cell-specific productivity, cellular and molecular biology, and accelerating process development timelines. Based on application, the continuous bioprocessing market is segmented into commercial and R&D. The commercial segment is estimated to account for the largest share of the overall market in 2021. Growing investments in constructing facilities compatible with continuous bioprocessing for the commercial manufacture of biopharmaceuticals is a key factor supporting this segment’s large share. The commercial applications segment is further categorized into vaccine manufacturing, mAb production, recombinant protein production, cell and gene therapy production, and plasma fractionation. In 2021, the mAb production segment is estimated to account for the largest share due to growing approvals for therapeutic antibodies and facility expansions for monoclonal antibody manufacturing. However, the R&D segment is projected to register a higher CAGR during the forecast period. Based on end user, the continuous bioprocessing market is segmented into pharmaceutical & biotechnology companies, CDMOs and CROs, and academic & research institutes. In 2021, the pharmaceutical and biotechnology companies segment is estimated to account for the largest share due to pharma and biopharma manufacturers' shift from batch to continuous processing, the growing focus of regulatory authorities on continuous bioprocessing, and growing investments incorporate continuous processing. Speak to Analysts: https://www.meticulousresearch.com/speak-to- analyst/cp_id=5079 Page 1 of 3 © Meticulous Research| sales@meticulousresearch.com
Continuous Bioprocessing Market –2021-2028 In recent years, the continuous bioprocessing market has also witnessed several new product launches, partnerships, agreements, expansions, and acquisitions. For instance, in May 2021, Thermo Fisher Scientific, Inc. (U.S.) and the University of California, San Francisco (UCSF) formed a strategic alliance to accelerate the development and manufacturing of cell- based therapies. key players operating in the global continuous bioprocessing market are 3M (U.S.), Cytiva (U.S.), Thermo Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), Sartorius AG (Germany), Repligen Corporation (U.S.), Eppendorf AG (Germany), Applikon Biotechnology (Netherlands), Pall Corporation (U.S.), and Bionet (U.S.) among others. Quick Buy –: https://www.meticulousresearch.com/Checkout/13717155 Scope of the Report: Continuous Bioprocessing Market, by Product •Filtration Systems and Consumables •Chromatography Systems and Consumables •Bioreactors •Sterilizers •Centrifuges •Incubators and Shakers •Mixing Systems •Cell Culture Media, Buffers, and Reagents •Other instruments and consumables Continuous Bioprocessing Market, by Application •Commercial oVaccines omAb production oRecombinant Protein Production oCell and Gene Therapy Production •R&D Continuous Bioprocessing Market, by End User •Pharmaceutical and Biotechnology Companies •Contract Development and Manufacturing Organizations and Contract Research Organizations Page 2 of 3 © Meticulous Research| sales@meticulousresearch.com
Continuous Bioprocessing Market –2021-2028 •Academic and Research Institutes To gain more insights into the market with a detailed table of content and figures, click here: https://www.meticulousresearch.com/product/continuous- bioprocessing-market-5079 Contact Us: Meticulous Research® Email- sales@meticulousresearch.com Contact Sales- +1-646-781-8004 Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous- research Page 3 of 3 © Meticulous Research| sales@meticulousresearch.com
